STOCKWATCH: The church of perverse success
This article was originally published in Scrip
Is it perverse to associate highly successful sectors with the potential to reverse that success? The fact that business cycles exist is one proof that it's not perverse to associate outsized success with at least mean reversion. Another is the 2013 rise of the technology sector and the more recent decline of the PC market which has led most industry-watchers to predict a very different 2014 for technology.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off?
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.